{"id":11329,"date":"2026-11-20T09:30:00","date_gmt":"2026-11-20T14:30:00","guid":{"rendered":"https:\/\/www.inflation.us\/news\/?p=11329"},"modified":"2026-11-20T09:34:57","modified_gmt":"2026-11-20T14:34:57","slug":"medicure-double-digits-coming-soon","status":"publish","type":"post","link":"https:\/\/www.inflation.us\/news\/articles\/medicure-double-digits-coming-soon\/","title":{"rendered":"Medicure Gained 5.71% Yesterday and Double Digits Coming Soon"},"content":{"rendered":"\n<div style=\"width:100%; max-width:650px; margin:0 auto; padding:0 10px; box-sizing:border-box; font-family:Arial,Helvetica,sans-serif; font-size:14px; line-height:1.65; color:#333333; -webkit-text-size-adjust:100%; -ms-text-size-adjust:100%; text-size-adjust:100%;\">\n\n<p style=\"margin:0 0 18px; padding:0;\">The last time <strong>Medicure (TSXV: MPH)<\/strong> became a <span style=\"color:#27ae60;\"><strong>100-bagger<\/strong><\/span> in 2013-2016, <span style=\"color:#27ae60;\"><strong>rising<\/strong><\/span> from <strong>$0.10 <span style=\"color:#27ae60;\">up to<\/span> $10.67<\/strong> for a <span style=\"color:#27ae60;\"><strong>gain of 10,570%<\/strong><\/span> in 42 months, its <span style=\"color:#2980b9;\"><strong>main catalyst<\/strong><\/span> was the <span style=\"color:#27ae60;\"><strong>acquisition<\/strong><\/span> of <strong>Apicore<\/strong>, an <strong>active pharmaceutical ingredients<\/strong> company based in East Windsor, NJ. <strong>Medicure <span style=\"color:#e74c3c;\">borrowed<\/span> money<\/strong> to <span style=\"color:#27ae60;\"><strong>acquire<\/strong><\/span> <strong>Apicore<\/strong> for approximately <strong>US$60 million<\/strong>, and <span style=\"color:#2980b9;\"><strong>successfully sold the business<\/strong><\/span> <strong>one year later<\/strong> for <strong>US$105 million<\/strong>, <span style=\"color:#27ae60;\"><strong>repaid<\/strong><\/span> the <span style=\"color:#e74c3c;\"><strong>debt<\/strong><\/span> plus interest and made a <strong>total net profit<\/strong> of <span style=\"color:#27ae60;\"><strong>US$43 million<\/strong><\/span> in one year, which is one of the many reasons <strong>Medicure is<\/strong> the <strong><span style=\"color:#2980b9;\">world&#8217;s<\/span> <span style=\"color:#27ae60;\">#1 best managed<\/span> biotech company<\/strong>.<\/p>\n\n<p style=\"margin:0 0 18px; padding:0;\">If <strong>Medicure <span style=\"color:#27ae60;\">gained by 10,570%<\/span><\/strong> from <strong>$0.10 <span style=\"color:#27ae60;\">up to<\/span> $10.67<\/strong> by <strong><span style=\"color:#27ae60;\">profiting<\/span> US$43 million<\/strong> on the <span style=\"color:#27ae60;\"><strong>acquisition<\/strong><\/span> and <span style=\"color:#2980b9;\"><strong>subsequent sale<\/strong><\/span> of a NJ pharmaceutical company, <strong>Apicore<\/strong>, in only twelve months&#8230; <span style=\"color:#2980b9;\"><strong>imagine how much<\/strong><\/span> <strong>MPH<\/strong> will <span style=\"color:#27ae60;\"><strong>gain<\/strong><\/span> over the next twelve months when it <span style=\"color:#27ae60;\"><strong>profits<\/strong><\/span> an estimated <strong>US$205 million<\/strong> from the <strong>Priority Review Voucher<\/strong> it will <span style=\"color:#27ae60;\"><strong>receive<\/strong><\/span> after <strong>MC-1 <span style=\"color:#27ae60;\">receives<\/span> FDA approval<\/strong>.<\/p>\n\n<p style=\"margin:0 0 18px; padding:0;\">Not only is <strong>Medicure<\/strong> set to <span style=\"color:#27ae60;\"><strong>make a 4.77x larger<\/strong><\/span> amount than what it made a decade ago when it <span style=\"color:#27ae60;\"><strong>rallied<\/strong><\/span> to <strong>$10.67 per share<\/strong>, but <strong>MPH<\/strong> has <strong><span style=\"color:#e74c3c;\">significantly less<\/span> shares outstanding<\/strong> today than it did back then. In 2019, the company <span style=\"color:#27ae60;\"><strong>repurchased<\/strong><\/span> <strong>4 million shares<\/strong> at <strong>$6.50 per share<\/strong> at a cost of <strong>CAD$26 million<\/strong>. Together with an <span style=\"color:#27ae60;\"><strong>additional<\/strong><\/span> <strong>751,800 shares <span style=\"color:#27ae60;\">repurchased<\/span><\/strong> in the <span style=\"color:#2980b9;\"><strong>open market<\/strong><\/span> at a cost of <strong>CAD$4.15 million<\/strong>, <strong>MPH <span style=\"color:#27ae60;\">repurchased<\/span> 4,751,800 shares<\/strong> at a cost of <strong>CAD$30.15 million<\/strong>.<\/p>\n\n<p style=\"margin:0 0 18px; padding:0;\">This means <strong>Medicure<\/strong> is one of the <span style=\"color:#2980b9;\"><strong>world&#8217;s most tightly held<\/strong><\/span> stocks. At any time we want, we can <span style=\"color:#27ae60;\"><strong>begin<\/strong><\/span> <span style=\"color:#2980b9;\"><strong>spreading word<\/strong><\/span> about <strong>Medicure<\/strong> to <strong>biotech investors<\/strong> on social media. There are <strong><span style=\"color:#e74c3c;\">very few<\/span> shares <span style=\"color:#2980b9;\">available<\/span><\/strong> to <span style=\"color:#27ae60;\"><strong>purchase<\/strong><\/span> in the <span style=\"color:#2980b9;\"><strong>open market<\/strong><\/span> between here and <strong>$10 per share<\/strong>.<\/p>\n\n<p style=\"margin:0 0 18px; padding:0;\">When <strong>Medicure<\/strong> made its previous <span style=\"color:#27ae60;\"><strong>run<\/strong><\/span> a decade ago, it <strong><span style=\"color:#e74c3c;\">did not<\/span> <span style=\"color:#27ae60;\">own<\/span> Marley Drug<\/strong>, its <strong>online telehealth pharmacy platform<\/strong> with <strong>30,000+ customers <span style=\"color:#2980b9;\">nationwide<\/span><\/strong> and <strong>three physical locations<\/strong> in North Carolina, Oregon, and Washington State. It <span style=\"color:#e74c3c;\"><strong>did not<\/strong><\/span> yet own <strong>ZYPITAMAG<\/strong>, the <strong><span style=\"color:#2980b9;\">popular patented<\/span> drug<\/strong> with <strong><span style=\"color:#27ae60;\">growing<\/span> sales<\/strong>. <strong>Medicure<\/strong> <span style=\"color:#e74c3c;\"><strong>did not<\/strong><\/span> have any <strong>Phase 3 trials<\/strong> <span style=\"color:#27ae60;\"><strong>taking place<\/strong><\/span> like it does today.<\/p>\n\n<p style=\"margin:0 0 18px; padding:0;\"><strong>Medicure<\/strong> has a <span style=\"color:#2980b9;\"><strong>100% chance<\/strong><\/span> of making <span style=\"color:#27ae60;\"><strong>very large gains<\/strong><\/span> in the days, weeks, and months ahead. It will be <strong>$30 per share<\/strong> by this time next year.<\/p>\n\n<p style=\"margin:20px 0 0; padding:12px 0 0; border-top:1px solid #dddddd; color:#777777; font-size:11px; line-height:1.6; font-style:italic;\">Past performance is not indicative of future results. NIA is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. NIA&#8217;s President has purchased 87,000 shares of MPH and intends to buy more shares. This communication is for informational and educational purposes only.<\/p>\n\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>The last time Medicure (TSXV: MPH) became a 100-bagger in 2013-2016, rising from $0.10 up to $10.67 for a gain of 10,570% in 42 months, its main catalyst was the acquisition of Apicore, an active pharmaceutical ingredients company based in East Windsor, NJ. Medicure borrowed money to acquire Apicore for approximately US$60 million, and successfully [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":11332,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[365,414],"class_list":["post-11329","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-biotech","tag-mph"],"_links":{"self":[{"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/posts\/11329","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/comments?post=11329"}],"version-history":[{"count":1,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/posts\/11329\/revisions"}],"predecessor-version":[{"id":11331,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/posts\/11329\/revisions\/11331"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/media\/11332"}],"wp:attachment":[{"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/media?parent=11329"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/categories?post=11329"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/tags?post=11329"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}